CompletedPhase 3NCT01621204

A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Studying Autoimmune thrombocytopenia

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: McMaster University
Principal Investigator: Donald M Arnold, MD MSc
McMaster University
Intervention: Eltrombopag(drug)
Enrollment: 74 enrolled
Eligibility: 18 years · All sexes
Timeline: 2012 – 2019

Study locations (10)

University of Alberta Hospital, Edmonton, Alberta, Canada
Vancouver General Hospital, Vancouver, British Columbia, Canada
Hamilton Health Sciences, Hamilton, Ontario, Canada
London Health Sciences Center, London, Ontario, Canada
Ottawa Hospital, Ottawa, Ontario, Canada
Sunnybrook Hospital, Toronto, Ontario, Canada
St.Micheal's Hospital, Toronto, Ontario, Canada
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
Jewish General Hospital, Montreal, Quebec, Canada
The Haga Hospital, The Hague, Netherlands

Collaborators

GlaxoSmithKline · Hamilton Health Sciences Corporation · Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01621204 on ClinicalTrials.gov

Other trials for Autoimmune thrombocytopenia

Additional recruiting or active studies for the same condition.

See all trials for Autoimmune thrombocytopenia →

← Back to all trials